Mediar Therapeutics
Boston, US · Founded 2018 · Delaware corporation · 58 employees on LinkedIn · 9 known investors
Mediartx develops novel therapies for patients with fibrotic diseases.
Founders & leadership
RB
Rahul Ballal, PhDCEO
PY
Paul Yaworsky, PhDinCSO
RB
Rahul BallalExecutive
BH
Brian HubbardNamed on SEC filing
SB
Stacey BrennerNamed on SEC filing
DD
David de GraafNamed on SEC filing
Board
MB
Michael BaranBoard director
MF
Meredith FisherBoard director
AJ
Andreas JurgeitBoard director
AK
CB
MB
Investors · 9
Longwood FundBoston
Mission BiocapitalSan Francisco · $500K
Novartis Venture FundBasel · $5M – $25Mvia Anja Koenig · board
Ono Venture Investment, Inc.South San Francisco
Pfizer Venture Investments$5M – $20M
ShangBay Capital LLCPalo Alto
Sofinnova PartnersParis · $540K – $27Mvia Maina Bhaman · board
Agent CapitalreportedWaltham
Pfizer Venturesreported
Reported raises · per SEC filings
Form D private placements$127.9M disclosed across 3 rounds · 2019–2025
▶$37.8MraisedDec 2025 · 18 investors · BiotechnologyRule 506(b)
▶$37.8MraisedDec 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas JurgeitDirector
- Bharat SrinivasaDirector
- Allan MarchingtonDirector
- Rahul BallalExecutive Officer, Director
- Cassidy BlundellDirector
- Maina BhamanDirector
- Adam CottonDirector
- Simon SturgeDirector
- Marie-Claire PeakmanDirector
- Offering amount
- $75.7M
- Amount sold
- $37.8M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$85MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simon SturgeDirector
- Michael BaranDirector
- Meredith FisherDirector
- Andreas JurgeitDirector
- Anja KonigDirector
- Rahul BallalExecutive Officer, Director
- Cassidy BlundellDirector
- Maina BhamanDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedFeb 2019 · 7 investors · OtherRule 506(b)
▶$5MraisedFeb 2019 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian HubbardDirector
- Stacey BrennerExecutive Officer
- Peter ParkerDirector
- David de GraafDirector
- Meredith FisherDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Mediar Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Mozart Therapeutics9 shared keywordsMozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.
Companies competing with Mediar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Mediar Therapeutics do?
- Mediartx develops novel therapies for patients with fibrotic diseases.
- Who are Mediar Therapeutics's investors?
- Mediar Therapeutics's investors include Longwood Fund, Mission Biocapital, Novartis Venture Fund, Ono Venture Investment, Inc., Pfizer Venture Investments, ShangBay Capital LLC, Sofinnova Partners, Agent Capital and 1 more.
- How much funding has Mediar Therapeutics raised?
- Mediar Therapeutics has disclosed $127.9M raised across 3 rounds.
- Where is Mediar Therapeutics headquartered?
- Mediar Therapeutics is headquartered in Boston, US.